The metabolic syndrome: Clinical appearance, diagnosis, pathomechanism;Metabolikus szindróma: Klinikai kép, diagnózis, patomechanizmus

Lege Artis Medicinae

Volumn 14, Issue 1, 2004, Pages 7-16

  Kékes, Ede ^a   Czuriga, István ^b  

^a Óbuda Health Centre   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

2T diabetes mellitus; Abdominal obesity; Adiponectine; Cholesterol; HPA axis; Hyperinsulinemia; Insulin resistance; Leptin; Lipid metabolism; Metabolic syndrome; Sympathetic overactivity; Triglyceride

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ACID; GLUCOSE; GLYCOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRIACYLGLYCEROL;

BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL FEATURE; GENETIC RISK; GLUCOSE BLOOD LEVEL; GLYCOGEN SYNTHESIS; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 1042265249     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1495-507.
2. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J 1991;212:1283-9.
3. Ferrannini G, et al. San Antonio Heart Study. J Hypertens 1990;8 (Suppl.7):169-73.
4. Pados Gy. A táplálkozással összefüggo legjelentosebb rizikófaktorok ischaemiás szívbetegsé gben: dyslipidaemia, obesitas, hypertonia és cukorintolerancia. Orv Hetil 1999;140:1563-72.
5. Kékes E. Berentey E. A magasvérnyomás-betegsé gben eloforduló cardiovascularis rizikófaktorok. Orv Hetil 2001;142:819-27.
6. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986;112:432-7.
7. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Eur Heart J 1998;19:SA2-11.
8. Assmann G, Schulte H, Funke H, Von Eckerstein. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19(Suppl.M):8-14.
9. De Fronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
10. De Fronzo RA. The metabolic cardiovascular syndrome: Insulin resistance, hyperinsulinemia, coronary heart disease, hypertension and dyslipidemia. Progr in Diabetes Mellitus 1992;2:1-12.
11. Berglund L, Lithell H. Prediction models for insulin resistance. Blood Pressure 1996;5:274-7.
12. Reims H, Hoieggen A, Fossum E, Kjeldsen SE. Assessment of insulin sensitivity by 90 min isoglycaemic hyperinsulinaemic glucose clamp in healthy young men. Blood Press 2000;9:121-3.
13. NHLBI Obesity Task Force. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. The evidence report. Obes Res 1998;6(Suppl.2):51-209.
14. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure indicating need for weight management. Br Med J 1995;311:158-61.
15. Han TS, van Leer EM, Seidell JC, Lean MEJ. Waist circumference action levels: the identification of cardiovascular risk factors prevalence study in a random sample. BMJ 1995;200:1401-5.
16. Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the Unites States, 1991-1998. JAMA 1999;282:1519-22.
17. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
18. Az MDT metabolikus munkacsoportja. A metabolikus szindróma definíciója, diagnosztikai kritériumrendszere és szurovizsgálata. Metabolizmus 2003;1:78-82.
19. De Backer G, Ambrosioni E, Borch-Jonsen K, et al. European guidelines on cardiovascular diasease prevention in clinical practice. Thirs Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.
20. Rösen P, Rösen R. The rationale for sympathetic modulation in NIDDM and the insulin resistance syndrome. Rev Contemp Pharmacother 1998;9:429-39.
21. Holman GD, Kasuga M. From receptor to transporter: insulin signaling to glucose transport. Diabetologia 1997;40:991-1003.
22. Taylor SI. Molecular mechanism of insulin resistance. Lessons from patients with mutations in the insulin receptor gene. Diabetes 1992;41:1373-90.
23. Vollenweider P, Raudin D, Tappy L, et al. Impaired insulin-induced sympathetic neural activation and vasodilatation in skeletal muscle in obese humans. J Clin Invest 1994;93:2365-71.
24. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171-8.
25. Himsworth HP. Diabetes mellitus: a differentiation to insulin sensitive and insulin insensitive types. Lancet 1936;1:127-30.
26. Hall JE, Brabds MW, Kivlingh SD, et al. Chronic hyperinsulinemia and blood pressure: interactions with catecholamins? Hypertension 1980;15:319-27.
27. Weidmann P, Boehlen LM, de Courten M. Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J 1993;125:1498-513.
28. O'Callaghan CJ, Komersova K, Louis WJ. Insulin as a pressor agent: Effects of physiological insulin concentration on finger blood pressure. Blood Press 1996;5(Suppl.1):18-22.
29. Massi-Benedetti M, Federici MO. Cardiovascular risk factors in type 2 diabetes: the role of hyperglycemia. Exp Clin Endocrinol Diabetes 1999;107(Suppl.4):120-3.
30. Lefebvre PJ, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diabetes Met 1998;15(Suppl.4):63-8.
31. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from CHD in subjects with type 2 diabetes and in non-diabetic subjects with and without myocardial infarction. N Engl J Med 1998;339:229-34.
32. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow up of participants in the Framingham Heart Study. Circulation 1992;16:959-67.
33. Yanovski JA, Yanovski SZ. Recent advances in basic obesity research. JAMA 1999;282:1504-6.
34. Ernsberger P, Koletsky R, Friedman JE. Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease: Rev Contemp Pharmacother 1998;9:411-28.
35. Oostrom AJH, Cabezas MC, Rabelink TJ. Insulin resistance and vessel endothelial function. J Royal Soc Med 2002;95(S42):54-9.
36. Beltowski J. Adiponectin and resistin: new hormones of white adipose tissue. Med Sci Monit 2003;9:55-61.
37. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300.
38. Duplus E, Glorian M, Forest C. FA regulation of gene transcription. J Biol Chem 2000;275:749-52.
39. Smith SA. Peroxisome proliferator-activated receptors and the regulation of lipid oxidation and adipogenesis. Biochem Soc Trans 1997;25:1242-8.
40. Ye JM, Doyle PJ, Iglesias MA, et al. PPAR alfa activation lowers muscle lipids and improves insulin sensitivity in high fat fed rats-comparison with PPAR gamma activation. Diabetes 2001;50:411-7.
41. Wilson PWF, Grundy SM. The metabolic syndrome. A practical guide to origins and treatment. Part I. Circulation 2003;108:1422-5.
42. Despres JP, Lamarch B, Mauriege P, et al. Risk factors for IHD: is it time to measure insulin? Eur Heart J 1996;17:1453-4.
43. Grassi G, Cattaneo BM, Seravalle G, et al. Obesity and the sympathetic nervous system. Blood Pressure 1996;5:43-7.
44. Nofer JR, Kehrel B, Fabker M, et al. HDL and atherosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002;161:1-16.
45. Lamarahe B, Morrjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease. A five year follow up of men in Quebec Cardiovascular Study. Circulation 1996;94:273-8.
46. Austin MA. The triglycerid, small dense lipoprotein, the atherogen lipoprotein phenotype. Current Atherosclerosis Reports 2000;2:200-7.
47. Jones PP, Snitker S, Skinner JS, Ravussen E. Gender differences in muscle sympathetic nerve activity: Effect of body fat distribution. Am J Physiol 1996;270:363-6.
48. Grassi G, Seravalle G, Dell'Oro R, et al. Adrenergic and reflex abnormalities in obesity related hypertension. Hypertension 2000;36:538-42.
49. Paolisso C, Manzella D, Rosarian MR, et al. Elevated plasma FA concentration stimulates the cardiac autonomic nervous system in healthy subjects. Am J Clin Nutr 2000;72:723-30.
50. Jouven X, Charles MA, Desnos M, Ducimetiere P. Circulating non esterified FA level, as a predictive risk factors for sudden death in the population. Circulation 2001;104:756-61.
51. Lansberg L, Krieger DR. Obesity, metabolism and the sympathetic system. Am J Hypertens 1989;2:125-32.
52. Julius S, Gudbrandsson T, Jamderson K, Shahab ST, Anderson O. The hemodinamic link between insulin resistance and hypertension. J Hypertens 1991;9:983-6.
53. Lembo C, Vecchione BM, Seravalle G, et. al. The crosstalk between insulin and the sympathetic nervous system: possible implications in the pathogenesis of essential hypertension. Blood Pressure 1996;5(Suppl.1):38-43.
54. Egan BM. Insulin resistance and the sympathetic nervous system. Current Hypertension Report 2003;5:247-54.
55. Despres JP. Potential contribution of expanded visceral adipose tissue to the atherothrombotic proinflammatory profile of visceral obese patients. Ann Endocrinol (Paris) 2001;61(1):31-8.
56. Kaski JC. Myocardial ischemia in the hypertensive patients: the role of coronary microcirculation abnormalities. Eur Heart J 1993;14(Suppl.J):32-7.
57. Brush JE, Cannon NO, Schenke WH, et al. Angina due to microvascular disease in hypertensive patients without left ventricular hypertrophy. New Eng J Med 1988;319:1302-8.
58. Julius S. Pathophysiology of the elevated sympathetic tone and the risk of coronary heart disease in hypertension. Cardiovascular Risk Factors 1995;2:2-10.
59. Slout RW, Bierman EL, Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 1975;36:319-27.
60. Björntorp P, Holm G, Rosmond R, Folkow B. Hypertension and the metabolic syndrome: closely related central origin? Blood Pressure 2000;9:71-83.
61. Björntorp P. Endocrine abnormalities of obesity. Metabolism 1995;44(Suppl.3):21-3.
62. Björntorp P. Visceralis obesity. A civilization syndrome. Obes Res 1993;1:206-22.
63. Halmos T. Metabolikus X szindróma. Budapest: Springer; 1995.
64. Parragh Gy, Balogh Z, Köbling T, Bajnok L. Elhízás és dyslipidaemia. Metabolizmus 2003;1:73-8.
65. Reaven G. Metabolic syndrome. Circulation 2002;106:286-92.